Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 5Leukemia, Hairy Cell 3Burkitt Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Carcinoma in Situ 2Breast Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Vomiting 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Sarcoma, Alveolar Soft Part 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Nausea and Vomiting 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Papillomavirus Infections 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm, Residual 1NSCLC 1Myelodysplastic Syndromes 1Mastocytosis, Systemic 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Cyclophosphamide 12fludarabine phosphate 7fludarabine 7venetoclax 6blinatumomab 6Rituximab 5Lenalidomide 5Cytarabine 5Dexamethasone 4Blood Specimen Collection 4Azacitidine 4obinutuzumab 3Radiotherapy 3Melphalan 3Immunotherapy, Adoptive 3pembrolizumab 2daratumumab 2Neoadjuvant Therapy 2Idarubicin 2Chemotherapy, Adjuvant 2Capecitabine 2trastuzumab deruxtecan 1tislelizumab 1tisagenlecleucel 1thymoglobulin 1tetrathiomolybdate 1talquetamab 1tagraxofusp 1sacituzumab govitecan 1sabatolimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × Diphenhydramine × 1 year × Clear all
NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
69 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡